Hospitalization and Healthcare Consumption Burden of Respiratory Syncytial Virus (RSV) in Adults Over 50 years in France (RESVYR Study)
Author(s)
Stephane Fievez, PhD1, Emmanuelle Blanc, PhD2, Paul Loubet, Dr3, Laurence Watier, Dr4, Louise BASCHET, MSc5, Clélia Bignon-Favary, PhD6, PIPPA MCKELVIE-SEBILEAU, Dr.6, LAUREN INCHBOARD, PhD6, MATHIAS VACHERET, PhD7.
1ACCESS AND VALUE -HEOR, Pfizer, Paris, France, 2VACCINES MEDICAL, PFIZER, Paris, France, 3Service des Maladies Infectieuses et Tropicales, CHU Nîmes Carémeau, Université de Montpellier, Nimes, France, 4Epidemiology and modelling of antibacterial evasion, Institut PASTEUR, PARIS, France, 5HORIANA, Bordeaux, France, 6HORIANA, BORDEAUX, France, 7VACCINES MEDICAL, PFIZER, PARIS, France.
1ACCESS AND VALUE -HEOR, Pfizer, Paris, France, 2VACCINES MEDICAL, PFIZER, Paris, France, 3Service des Maladies Infectieuses et Tropicales, CHU Nîmes Carémeau, Université de Montpellier, Nimes, France, 4Epidemiology and modelling of antibacterial evasion, Institut PASTEUR, PARIS, France, 5HORIANA, Bordeaux, France, 6HORIANA, BORDEAUX, France, 7VACCINES MEDICAL, PFIZER, PARIS, France.
OBJECTIVES: Our study describes the characteristics of French adults aged ≥50 years hospitalized for Respiratory Syncytial Virus (RSV) infection between 2015 and 2022 and their reimbursed healthcare pathways in ambulatory and hospital settings.
METHODS: In this retrospective observational study using data from the French National Health Data System (SNDS), we identified patients hospitalized for RSV and analyzed their hospital stays and community healthcare consumptions. Patients were classified into risk groups according to the reported comorbidities and by age group. Analyzing post-hospitalization healthcare consumption, we describe differential healthcare use and global direct medical costs (national insurance perspective compared to a 30-day reference period prior to RSV infection.
RESULTS: Between 2015 and 2022, 15,509 RSV hospitalizations were identified, mainly for patients 65-74 years (20.9%) and ≥75 years (61.7%). Most patients (92.2%) had comorbidities (average of 2.6 (SD1.7) per patient) and 2,467 (15.9%) patients were immunocompromised. Mean hospitalization was 15.0 (SD 15.6) days and 25.4% of patients had at least one intensive care admission, patients aged 50-59 being particularly affected (37.9%). In-hospital mortality rate was 8.6% and 3.8% of people alive at discharge died within 30 days. During this period, 17.8% of patients were re-hospitalized for any cause, including 7.8% for cardiorespiratory causes. Mean hospitalization cost was 6,876 € (SD 9,346). Increased healthcare expenditure in the 30 days post hospitalization (mean increase of 2,357 € (SD 9,278) was observed across all patient ages and risk profiles.
CONCLUSIONS: RSV infection represents a significant hospitalization and economic burden, particularly for patients 75 years and older. Patients aged 50-59 years are also affected with high use of ICU and with additional healthcare costs. These results highlight the importance of considering both comorbidities and age in prevention measures to reduce the impact of these infections.
METHODS: In this retrospective observational study using data from the French National Health Data System (SNDS), we identified patients hospitalized for RSV and analyzed their hospital stays and community healthcare consumptions. Patients were classified into risk groups according to the reported comorbidities and by age group. Analyzing post-hospitalization healthcare consumption, we describe differential healthcare use and global direct medical costs (national insurance perspective compared to a 30-day reference period prior to RSV infection.
RESULTS: Between 2015 and 2022, 15,509 RSV hospitalizations were identified, mainly for patients 65-74 years (20.9%) and ≥75 years (61.7%). Most patients (92.2%) had comorbidities (average of 2.6 (SD1.7) per patient) and 2,467 (15.9%) patients were immunocompromised. Mean hospitalization was 15.0 (SD 15.6) days and 25.4% of patients had at least one intensive care admission, patients aged 50-59 being particularly affected (37.9%). In-hospital mortality rate was 8.6% and 3.8% of people alive at discharge died within 30 days. During this period, 17.8% of patients were re-hospitalized for any cause, including 7.8% for cardiorespiratory causes. Mean hospitalization cost was 6,876 € (SD 9,346). Increased healthcare expenditure in the 30 days post hospitalization (mean increase of 2,357 € (SD 9,278) was observed across all patient ages and risk profiles.
CONCLUSIONS: RSV infection represents a significant hospitalization and economic burden, particularly for patients 75 years and older. Patients aged 50-59 years are also affected with high use of ICU and with additional healthcare costs. These results highlight the importance of considering both comorbidities and age in prevention measures to reduce the impact of these infections.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH129
Topic
Economic Evaluation, Epidemiology & Public Health, Real World Data & Information Systems
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines